

Financial Briefing for the Second Quarter of the Fiscal Year Ended March 31, 2024 (Fiscal 2023)

Yasuo Takehana President and COO

November 8, 2023

KISSEI PHARMACEUTICAL CO., LTD.



Overview of the Financial Results for the Second Quarter of Fiscal 2023



- **1.** Consolidated Results
 - ✓ Net sales: ¥36,978 million (+12.5% YoY)
 - ✓ Operating profit: ¥2,015 million
 - Increased sales in the Pharmaceutical Business and other businesses
- 2. Pharmaceutical Business
 - ✓Net sales: ¥30,765 million (+10.1% YoY)
 - Key products: **Beova**[®], a treatment for overactive bladder
 - New products: **TAVNEOS**[®], a treatment for MPA^{*1} and GPA^{*2} (restrictions of dosage period lifted in June 2023)
 - **CAROGRA**[®], a treatment for ulcerative colitis (restrictions of dosage period lifted in June 2023)
 - **TAVALISSE**[®], a treatment for chronic ITP^{*3} (launched in April 2023)

Overview of the Financial Results for the Second Quarter of Fiscal 2023



3. Development pipeline

- **KORSUVA**[®] (treatment for uremic pruritis^{*}): New Drug Application (NDA) approved (September 2023), preparations for launch underway
- **Rovatirelin** (treatment for spinocerebellar ataxia): NDA withdrawn, possibility of conducting additional trials currently under discussion

4. Overseas earnings

✓ Expand overseas earnings base through original products

• Linzagolix (treatment for uterine fibroids)

Europe: Launch of the drug as a treatment for uterine fibroids scheduled for fiscal 2024 via Theramex (marketing authorization application approved in June 2022)

Consolidated Financial Results for the Second Quarter of Fiscal 2023



(millions of yen)

	Second quarte	er of fiscal 2022	Second quarter of fiscal 2023						
	Result	Ratio to sales	Plan	Result	Ratio to net sales	YoY			
Net sales	32,864	100.0 %	35,500	36,978	100.0 %	12.5 %			
[Pharmaceutical Business]	[27,946]	[85.0 %]	[29,500]	[30,765]	[83.2 %]	[10.1 %]			
Pharmaceuticals ^{*1}	23,550	71.7 %	25,000	26,420	71.4 %	12.2 %			
Therapeutic and care foods	1,766	5.4 %	1,800	1,763	4.8 %	(0.1 %)			
Technical fees ^{*2}	220	0.7 %	500	171	0.5 %	(22.2 %)			
Other ^{*3}	2,410	7.3 %	2,200	2,410	6.5 %	0.0 %			
Cost of sales	16,680	50.8 %	18,500	18,677	50.5 %	12.0 %			
Gross profit	16,184	49.2 %	17,000	18,300	49.5 %	13.1 %			
Selling, general and administrative expenses	16,810	51.1 %	16,100	16,284	44.0 %	(3.1 %)			
[R&D expenses]	[5,200]	[15.8 %]	[4,500]	[4,499]	[12.2 %]	[(13.5 %)]			
Operating profit (loss)	(625)	_	900	2,015	5.5 %	-			
Ordinary profit	308	0.9 %	1,500	3,465	9.4 %	-			
Quarterly profit ^{*4}	3,326	10.1 %	4,800	5,678	15.4 %	70.7 %			

Comprehensive income

26

9,608

*1 Including active pharmaceutical ingredients (APIs) and bulk exports

*2 Includes revenue contracting fees related to out-licensing, milestone payments, and running royalties

*3 Includes revenue from supply to domestic sales partners and revenue from co-promotion fees


*4 Refers to quarterly profit attributable to owners of parent

Please refer to pages 2, 3, and 8 of the Supplementary Explanatory Materials on Financial Results


3

Consolidated Financial Results Compared with Fiscal 2022





Consolidated Quarterly Profit Attributable to Owners of Parent Compared with Second Quarter of Fiscal 2022 KISSEI



Revised Plan for Fiscal 2023 (Consolidated)




(millions of yen)

	Fisca	al 2022	Fiscal 2023					
	Result	Ratio to net sales	Initial plan	Revised plan	Ratio to net sales	YoY		
Net sales	67,493	100.0 %	74,500	77,500	100.0 %	14.8 %		
[Pharmaceutical Business]	[56,243]	[83.3 %]	[62,500]	[65,000]	[83.9 %]	[15.6 %]		
Pharmaceuticals	47,077	69.8 %	51,500	54,500	70.3 %	15.8 %		
Therapeutic and Care Foods	3,461	5.1 %	3,600	3,600	4.6 %	4.0 %		
Technical Fees	1,053	1.6 %	3,000	1,900	2.5 %	80.4 %		
Other	4,650	6.9 %	4,400	5,000	6.5 %	7.5 %		
Cost of sales	35,118	52.0 %	37,600	39,300	50.7 %	11.9 %		
Gross profit	32,374	48.0 %	36,900	38,200	49.3 %	18.0 %		
Selling, general and administrative expenses	33,503	49.6 %	32,700	33,200	42.8 %	(0.9 %)		
[R&D expenses]	[10,391]	[15.4 %]	[9,200]	[9,400]	[12.1 %]	[(9.5 %)]		
Operating profit (loss)	(1,129)	-	4,200	5,000	6.5 %	_		
Ordinary profit	598	0.9 %	5,200	6,700	8.6 %	_		
Profit attributable to owners of parent	10,528	15.6 %	10,600	10,000	12.9 %	(5.0%)		

Please refer to pages 2, 3, and 8 of the Supplementary Explanatory Materials on Financial Results

Pharmaceutical Business | Toward Sustainable Growth





*1 Total domestic sales for the Company


*2 Total for drugs launched since the beginning of fiscal 2022 (TAVNEOS®, CAROGRA®, TAVALISSE®, KORSUVA®)

Achieve sustainable growth

7

Beova[®] | Becoming the Most-Prescribed Treatment for Overactive Bladder

Net Sales (Sales by Kissei) and Share of Patients^{*1} (Two Companies)



*1 Share of patients receiving overactive bladder treatment. Compiled in-house based on JPM PATDY 2019/10-2023/8, Reprinted with permission, Copyright © 2023 IQVIA.

KISS

Status of Introduction of New Products to the Market | Dealing with Intractable Diseases KISSEI


	TAVNEOS®	TAVALISSE®	CAROGRA®
Common concepts	who have an inadequate resp treatments by utilizing differe	dilemma of choosing the efficacy	heir diseases with conventional
Status	activities to provide scienti	via the Rare Diseases Project [*] fic information based on treat d for meeting unmet needs, sp	ment needs and policies



* A department responsible for planning marketing strategies in the rare disease area, collecting information nationwide, and providing specialized and advanced information

TAVNEOS[®] | Clinical Guidelines for ANCA-Associated Vasculitis 2023






KISSEI

10

TAVNEOS[®] | Status of Introduction to the Market





- June 2023: Restriction on dosage period lifted
- Target patients (initial goal): Patients who require remission induction therapy
- Number of target patients: Approx. 3,300 people per year (approx. 2,000 new patients + 1,300 patients with recurrences)*1*2

Estimated Number of Patients Treated (as of September 2023)^{*3} Approx. **1,400** people

> Plan for fiscal 2023: ¥5.0 billion (+385.9% YoY)


*1 Fiscal 2021 Report on Public Health Administration and Services: Number of patients receiving medical expense payments for designated intractable diseases (as of the end of March 2022)

*2 Calculations derived from Rheumatology, 2011; 50, 1916-1920, Arthritis Res Ther., 2015; 17, 305, and J Rheumatol., 2018; 45(4): 521-528

*3 In-house total


CAROGRA[®] | Diagnostic Criteria and Treatment Guidelines for Ulcerative Colitis/Crohn's Disease

Ulcerative Colitis Flow Chart



Partially adapted from page 17 of an assigned research report for Investigation and Research on Intractable Inflammatory Bowel Disease (Hisamatsu Group) as part of the Research Program on Rare and Intractable Diseases, funded by the Ministry of Health, Labour and Welfare's Health, Labor and Welfare Sciences Research Grants system, fiscal 2022


CAROGRA® | Status of Market Introduction



TAVALISSE® | Positioning



Position drug as a second-line treatment as an orally administered drug with a novel mechanism of action that inhibits platelet destruction associated with ITP



TAVALISSE[®] utilizes a novel mechanism of action to inhibit platelet destruction in a manner similar to steroids

- Patients with an insufficient response to or who are unable to tolerate other treatments
- Patients who need to maintain or reduce steroid dosage
- Patients deemed suitable for an orally administered second-line treatment

Kashiwagi Hirokazu et al, Jpn J Clin Hematol. 2019; 60(8), 877-896. (partially adapted)

*1 In no particular order *2 Drugs not covered by


insurance

*3 Thrmbopoietin

TAVALISSE[®] | Status of Introduction to the Market




- Date of launch: April 6, 2023
- TAVALISSE[®] utilizes a novel mechanism of action, offering new treatment options and assistance in cases where conventional treatments prove insufficient. As a result, the number of facilities administering the drug and the number of patients receiving the drug have increased beyond expectations



KORSUVA® | **Product Overview**

September 25, 2023: Acquired manufacturing and marketing approval in Japan


Product Name	KORSUVA® IV injection syringe for dialysis 17.5µg, 25.0µg, and 35.0µg						
Generic Name	Difelikefalin acetate (JAN)						
Indications	Improvement of pruritus in hemodialysis patients (limited to cases in which the effects of existing treatments are insufficient)						
	Normally, inject difelikefalin with the below table dosage to adults into the venous side of the dialysis circuit during return transfusion at the end of dialysis three times a week.						
Dosage and	Dry weight	Dosage					
Administration	Under 45 kg	17.5 µg					
	45 kg or higher but under 65 kg	25.0 µg					
	65 kg or higher but under 85 kg	35.0 µg					
	85 kg or higher	42.5 µg]				
Mechanism of Action	Helps ease itching (pruritis) by acting upon kappa opioid receptors						
Overseas Status of Approval and Drug Launch	Drug is approved in 39 countries/regions and has been launched in nine of these countries/regions. Main countries of sale include the United States (as KORSUVA [™]) and European countries such as Austria, Germany, Sweden, France, Finland, the Netherlands, Switzerland (as Kapruvia [®])						



Based on A. Albert-Vartanian, et al., J Clin Pharm Ther., 2016; 41: 371-382.

KORSUVA[®] | About Uremic Pruritis in Dialysis Patients

- Approximately 70% of patients undergoing dialysis experience pruritis, of which 30% experience severe pruritis.*1
- Percentage of patients suffering from pruritis: 75%*2



- Severe and prolonged pruritis can lead to a drop in a patient's quality of life, as well as the following negative effects^{*2}
 - Sleep deprivation
 - Depression
 - Fainting and dizziness
 - Fatigue

*1 I. Narita, et al. *Kidney Int.*, 2006 May; 69(9):1626-32
*2 Adapted from N. Sukul, et al., *Kidney Med.*, 2020 Nov. 21; 3(1):42-53.
"Dialysis Outcomes and Practice Patterns Study" (data for Japan)

17

KORSUVA® | Domestic Phase III Clinical Trial \sim NRS Score \sim

Drywoight	Dosage				
Dry weight	KORSUVA group	Placebo group			
Less than 45 kg	17.5 µg	0.0 µg			
Over 45 kg but less than 65 kg	25.0 µg	0.0 µg			
Over 65 kg but less than 85 kg	35.0 µg	0.0 µg			
Over 85 kg	42.5 µg	0.0 µg			

46

34

67

63


26

69

67


Dosage: Based on dry weight (see right table) Dosage period and method: Six-week double-blind phase (three times a week, 18 times total), followed by a 52-week continuation phase (three times a week, 156 times total); drug is administered via intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis treatment Primary endpoint: Change in the Numerical Rating Scale (NRS) score for itching at week four

Design: Double-blind, placebo-controlled, multicenter, randomized, parallel-group comparative study (double-blind phase)



followed by a multicenter, open-label study (continuation phase) Participants: Hemodialysis patients with previously treated pruritus

Primary endpoint (other evaluation variables): Change in NSR score (double-blind phase + continuation phase)



KORSUVA-KORSUVA group Placebo-KORSUVA® group Mean + standard deviation

18

(Weeks)

58

58

50

58

46

66

57

KISSEI

In-Company data from Phase III clinical trials (MR13A9-5). NDA approved September 25, 2023, CTD2.7.6.14.

34

18

76


70

KORSUVA® | Domestic Phase III Clinical Trial \sim Quality of Life Score \sim



Total Skindex-16 Score

 Secondary endpoint: Change in total Skindex-16 score (double-blind phase, final assessment)



continuation phase)

Change from baseline was measured using total Skindex-16 scores.

Secondary endpoint: Change in total Skindex-16 score (double-blind phase +

In-Company data from Phase III clinical trials (MR13A9-5). NDA approved September 25, 2023, CTD2.7.6.14.

New Drug Development (In-Company)



		Development stage								
Product name /	—	Phase					NDA in	NDA		
Generic name / Development code	Expected indications	I	II		III		process	approved	Development classification	
KORSUVA [®] / Difelikefalin / MR13A9	Pruritus in hemodialysis patients*								In-licensed / Co-development with Maruishi Pharmaceutical	
CG0070	Non-muscle-invasive bladder cancer								In-licensed / CG Oncology Joint global Phase III clinical trial	
Linzagolix /	Uterine fibroids								Original product	
KLH-2109	Endometriosis								Original product	
KDT-3594	Parkinson's disease								Original product	
KSP-0243	Ulcerative colitis								Original product	

Changes from May 2023

KORSUVA® (uremic pruritis in dialysis patients*) NDA in process --> NDA approved

Rovatirelin (spinocerebellar ataxia) NDA in process --> NDA withdrawn, discussions into the possibility of additional clinical trials underway (removed from table)

* Indications: pruritus in hemodialysis patients (limited to the improvement of symptoms when conventional treatments are inadequate)

New Drug Development (Out-Licensing)

Generic name /	Expected	Countries	Clinical trials under		Phase		Preparation to submit	NDA in	NDA	Partner
Development cod	e indications	and regions	preparation	Ι	II	III	application	process	approved	company
		Europe								Theramex
Linzagolix / KLH-2109	Uterine fibroids	China								Bio Genuine
		Taiwan								Synmosa Biopharma
	Endometriosis	Europe								Theramex
		China								Bio Genuine
Silodosin	Dysuria associated with BPH ^{*1}	Vietnam, other countries								Eisai
Fostamatinib / R788	Chronic ITP ^{*2}	South Korea								JW Pharmaceutical
		China, other countries								Inmagene Biopharmaceuticals
KDT-3594	Parkinson's disease	China, other countries								AffaMed Therapeutics


Changes from May 2023

Linzagolix (endometriosis) Phase I clinical trials --> Phase III clinical trials (China)

*1 Benign prostatic hyperplasia

*2 Idiopathic thrombocytopenic purpura

Improving the Quality and Speed of Drug Discovery Research through DX




Efforts to Increase Corporate Value



Past investments have enabled us to transition to a growth phase. We will continue investments toward stable future growth.

- ✓ Improve corporate value and realize a sustainable society
- ✓ Conduct management mindful of the cost of capital and stock price








The forward-looking statements in these materials are based on Kissei's analysis of existing information and various trends as of November 2023. Actual results may differ from forecasts due to risks and uncertainties that may affect business. Although drug information, including information pertaining to drugs under development, is reported in these materials, the contents are not intended as marketing or medical advice.



Appendix

Indicator for Assessing Improvement of Pruritis KISSEI



Quality of Life Assessment Score

Skindex-16 Score

Patients reflect on their skin symptoms over the past week and complete a 16-item assessment, rating how bothered they were regarding each item on a scale of 0 (never bothered) to 6 (always bothered). **Over the past week, how often did you feel bothered regarding each of the following items?**

- 1. Skin itching
- 2. Burning or stinging sensation in the skin
- 3. Skin pain
- 4. Skin irritation
- 5. Persistent, recurrent, or worsening skin symptoms
- 6. Worry over skin symptoms worsening, spreading further, leaving marks, or reappearing unpredictably
- 7. Concern over skin appearance
- 8. Frustration over skin symptoms

- 9. Embarrassment over skin symptoms
- 10. Annoyance over skin symptoms
- 11. Depression over skin symptoms
- 12. Changes in social relationships (with family, friends, etc.) due to skin symptoms
- 13. Loss of desire to be with people due to skin symptoms
- 14. Difficulty showing love and affection openly due to skin symptoms
- 15. Impact on daily activities from skin symptoms
- 16. Difficulty working or doing enjoyable activities due to skin symptoms

The assessment is divided into three subscales: symptom (items 1 to 4), emotional (items 5 to 11), and functional (items 12-16). For each item, patients provide a score along a seven-point scale ranging from 0 (never bothered) and 6 (always bothered). Copyright holder (Japanese version): Yuko Higaki (Tokyo Women's Medical University, Tokyo, Japan); publisher: Medical Professional Relations Inc.

Adapted from Y. Higaki, et al. J Dermatol., 2002; 29: 693-698